Pages that link to "Q83523415"
Jump to navigation
Jump to search
The following pages link to FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer (Q83523415):
Displaying 50 items.
- Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide (Q21195191) (← links)
- Combination anastrozole and fulvestrant in metastatic breast cancer (Q24595386) (← links)
- ABC3 Consensus Commented from the Perspective of the German Guidelines (Q26768665) (← links)
- Optimal management of hormone receptor positive metastatic breast cancer in 2016 (Q26777683) (← links)
- Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer (Q26785496) (← links)
- Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options (Q26995549) (← links)
- Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers (Q28069856) (← links)
- Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant (Q28076777) (← links)
- Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines (Q28080469) (← links)
- Clinical utilities of aromatase inhibitors in breast cancer (Q28081168) (← links)
- Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers (Q28081872) (← links)
- Fulvestrant for hormone-sensitive metastatic breast cancer. (Q30239835) (← links)
- ABC3 Consensus: Assessment by a German Group of Experts (Q30315301) (← links)
- AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013 (Q30317569) (← links)
- Emerging therapies for breast cancer (Q33617949) (← links)
- Fulvestrant in advanced breast cancer: evidence to date and place in therapy (Q33887675) (← links)
- Breast Cancer 2012 - New Aspects (Q34209663) (← links)
- Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. (Q34657786) (← links)
- Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer (Q35687540) (← links)
- The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer (Q35827822) (← links)
- Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer (Q35958082) (← links)
- Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study (Q36534686) (← links)
- New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus (Q36547566) (← links)
- Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. (Q36646986) (← links)
- A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. (Q36903310) (← links)
- Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. (Q36924682) (← links)
- Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. (Q36933778) (← links)
- N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. (Q37200495) (← links)
- Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis (Q37470730) (← links)
- Everolimus plus exemestane in postmenopausal patients with HR( ) breast cancer: BOLERO-2 final progression-free survival analysis (Q37501868) (← links)
- Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial (Q37532641) (← links)
- Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer (Q37570653) (← links)
- Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ. (Q37636714) (← links)
- Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer (Q38100711) (← links)
- Luminal breast cancer: from biology to treatment (Q38123680) (← links)
- Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer (Q38352305) (← links)
- Challenges in the management of advanced, ER-positive, HER2-negative breast cancer (Q38502890) (← links)
- Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer (Q38577715) (← links)
- Metastatic breast cancer: The Odyssey of personalization (Q38901163) (← links)
- Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR /HER2- Advanced Breast Cancer (Q39172983) (← links)
- Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer (Q39185424) (← links)
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult (Q44699072) (← links)
- Metastatic breast cancer: Endocrine therapy landscape reshaped (Q45072397) (← links)
- Combination endocrine treatments unproven in breast cancer (Q45172965) (← links)
- SEOM clinical guidelines for the management of metastatic breast cancer 2013. (Q46011982) (← links)
- Post-menopausal breast cancer: from estrogen to androgen receptor. (Q47094109) (← links)
- Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review (Q49632496) (← links)
- New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. (Q52942118) (← links)
- A Review of Fulvestrant in Breast Cancer. (Q53733893) (← links)
- CDK4/6 inhibitors in luminal breast cancer. (Q54301108) (← links)